GROWTH FACTOR ENHANCED SOLDERS FOR LASER TISSUE WELDING

Information

  • Research Project
  • 2777011
  • ApplicationId
    2777011
  • Core Project Number
    R44DK050505
  • Full Project Number
    2R44DK050505-02A1
  • Serial Number
    50505
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1995 - 28 years ago
  • Project End Date
    8/31/2000 - 23 years ago
  • Program Officer Name
    SMITH, PHILIP F.
  • Budget Start Date
    9/30/1998 - 25 years ago
  • Budget End Date
    8/31/1999 - 24 years ago
  • Fiscal Year
    1998
  • Support Year
    2
  • Suffix
    A1
  • Award Notice Date
    9/29/1998 - 25 years ago
Organizations

GROWTH FACTOR ENHANCED SOLDERS FOR LASER TISSUE WELDING

DESCRIPTION (adapted from applicant's abstract): The primary objective of this proposal is to integrate the use of a temperature-controlled laser welding system with a novel type of tissue solder to provide enhanced healing for laser-assisted wound closure. By adding growth factors to the tissue solder presently being used and carefully controlling the weld temperature to avoid thermal denaturation of the growth factors, a non- immunologic, biologically active structure results. Albumin solders, currently used in laser-assisted repairs, appear to be optimal carriers for in situ delivery of growth factors. In phase I, this investigative team demonstrated successful in vivo delivery of biologically active growth factors to wounds via denatured albumin-based solders, and also showed accelerated healing. In this revised phase II application, the group proposes to study in detail factors that affect in situ delivery of growth factors in this system, and thereby optimize the technology for laser-assisted wound healing. The specific aims of their proposal are to: 1) develop in vitro test methods to analyze the use of human serum albumin (HSA) as a delivery vehicle for TGF-beta1 and other growth factors; and 2) determine the optimal parameters for the TGF-beta1-enhanced HSA solders for accelerated wound repair in vivo models. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    ABIOMED, INC.
  • Organization Department
  • Organization DUNS
    050636737
  • Organization City
    DANVERS
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01923
  • Organization District
    UNITED STATES